Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02109770 · ClinicalTrials.gov registry record

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

A clinical trial, sponsored by Natera.

Completed
Registry status
216
Enrollment target

NCT02109770: Completed study, sponsored by Natera.

NCT02109770 is a clinical trial that has completed, run by Natera. The registered enrollment target is 216 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02109770 has completed, sponsored by Natera.

COMPLETED
Registry status
216 participants
Enrollment target

Study Summary

The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2012-10
Est. Completion 2019-08
Natera

27 total trials

What the finished NCT02109770 record still lists

NCT02109770 is an observational study that tracks outcomes without assigning an intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02109770 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02109770 about?

NCT02109770 is a clinical study titled "Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA". The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

What is the current status of trial NCT02109770?

This trial is currently completed. The enrollment target is 216 participants. The study started on 2012-10. Estimated completion is 2019-08.

Who is sponsoring clinical trial NCT02109770?

This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02609685 · 216 participants · NA

    Active Surveillance of Papillary Thyroid Microcarcinoma

  • NCT04994873 · 216 participants · NA

    Skills to Enhance Positivity in Suicidal Youth

  • NCT05264779 · 216 participants · NA

    The Periviable GOALS Decision Support Tool

  • NCT05434130 · 216 participants · Phase 2

    Modulating Exercise Dosage to Improve Concussion Recovery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02109770, the US trial registry maintained by the National Library of Medicine. NCT02109770 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.